<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786101</article-id><article-id pub-id-type="doi">10.7759/cureus.76772</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject></subj-group><subj-group><subject>Genetics</subject></subj-group><subj-group><subject>Rheumatology</subject></subj-group></article-categories><title-group><article-title>Adult-Onset Episodic Rhabdomyolysis in a Patient With a Heterozygous Lipin 1 (LPIN1) Mutation: A Case Report</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Bareja</surname><given-names>Naman</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Chionatos</surname><given-names>Rafail A</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Valhuerdi Porto</surname><given-names>Camelia</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Srinivasan</surname><given-names>Nikita</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ghasemi</surname><given-names>Mehdi</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Neurology, Tufts Medical Center, Boston, USA </aff><aff id="aff-2">
<label>2</label>
Neurology, Lahey Hospital and Medical Center, Burlington, USA </aff><author-notes><corresp id="cor1">
Mehdi Ghasemi <email>m82.ghasemi@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>1</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>1</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><elocation-id>e76772</elocation-id><history><date date-type="accepted"><day>1</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Bareja et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Bareja et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/331160-adult-onset-episodic-rhabdomyolysis-in-a-patient-with-a-heterozygous-lipin-1-lpin1-mutation-a-case-report">This article is available from https://www.cureus.com/articles/331160-adult-onset-episodic-rhabdomyolysis-in-a-patient-with-a-heterozygous-lipin-1-lpin1-mutation-a-case-report</self-uri><abstract><p>Lipin-1 (<italic>LPIN1</italic>) is essential in lipid metabolism, with mutations commonly causing severe, recurrent rhabdomyolysis, especially in children. Here, we present a rare case of adult-onset myopathy and rhabdomyolysis in a 48-year-old male firefighter, a heterozygous carrier of an <italic>LPIN1</italic> exon 18 deletion. The patient experienced fatigue, muscle loss, and exercise intolerance over two to three&#x000a0;years. Initial evaluations revealed mildly elevated creatine kinase (CK) levels (297 U/L), with unremarkable results from further tests, including electromyography, antinuclear antibodies, myasthenia gravis antibody, and myositis antibody panels. Six months later, he had worsening muscle stiffness, pain, and darkened urine. In the emergency department, his CK was 4000 U/L, with elevated aldolase and transaminases. Hospitalization and hydration treatment normalized his CK levels. Genetic testing through a Comprehensive Neuromuscular Disorder Panel identified a heterozygous <italic>LPIN1</italic> exon 18 deletion. To our knowledge, this case is significant as the first reported instance of adult-onset myopathy and rhabdomyolysis in a heterozygous <italic>LPIN1</italic> carrier without statin exposure. While <italic>LPIN1</italic> mutations typically cause pediatric-onset rhabdomyolysis, this case highlights the need to consider <italic>LPIN1</italic> mutations in adults with episodic myopathy and rhabdomyolysis when other causes are ruled out. Genetic testing is crucial for diagnosis and management.</p></abstract><kwd-group kwd-group-type="author"><kwd>hyperckemia</kwd><kwd>lipin-1</kwd><kwd>lpin1 mutation</kwd><kwd>peripheral muscle weakness</kwd><kwd>rhabdomyolysis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Lipin-1 (<italic>LPIN1</italic>) is an important protein comprising 890 amino acids and is predominantly expressed in skeletal muscle, adipose tissue, liver, and myocardium [<xref rid="REF1" ref-type="bibr">1</xref>]. The <italic>LPIN1 </italic>gene is located on chromosome 2p25.1 and encodes the enzyme <italic>LPIN1</italic>. This enzyme plays a pivotal role in lipid metabolism by converting phosphatidic acid to diacylglycerol, an essential precursor for both triglycerides and phospholipids [<xref rid="REF2" ref-type="bibr">2</xref>]. Mutations in the <italic>LPIN1 </italic>gene are recognized as one of the most common causes of recurrent rhabdomyolysis in the pediatric population [<xref rid="REF3" ref-type="bibr">3</xref>]. Typically, patients with homozygous or compound heterozygous <italic>LPIN1</italic> mutations experience episodes of severe rhabdomyolysis (creatine kinase (CK) levels exceeding 10,000 U/L), often precipitated by triggers such as febrile illness, intense physical exercise, or fasting. Notably, the onset of these episodes generally occurs before the age of six, indicating an early manifestation of the disorder [<xref rid="REF3" ref-type="bibr">3</xref>,<xref rid="REF4" ref-type="bibr">4</xref>]. Despite the severity of these episodes, patients are usually asymptomatic between occurrences, suggesting that the condition is episodic in nature.</p><p>It is noteworthy that up to 40% of individuals who are heterozygous carriers of <italic>LPIN1 </italic>mutations may exhibit symptoms such as muscle cramps, myalgias, and exercise-induced muscle pain [<xref rid="REF4" ref-type="bibr">4</xref>]. Additionally, statin-induced myopathy has been documented in a heterozygous carrier [<xref rid="REF5" ref-type="bibr">5</xref>]. We present a unique case that adds to the complexity of <italic>LPIN1</italic>-related disorders. This case involves an adult-onset recurrent rhabdomyolysis in a heterozygous patient who had no prior exposure to statins. This observation is particularly noteworthy as it suggests that even in the absence of common triggers like statin use, heterozygous <italic>LPIN1</italic> mutations can lead to significant muscle pathology later in life. This case highlights the variability in clinical presentation and the need for further research to understand the underlying mechanisms and potential risk factors associated with <italic>LPIN1 </italic>mutations.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 48-year-old male firefighter sought medical advice initially from his primary care physician in June 2023 due to a three-year history of fatigue, exercise intolerance, and muscle mass loss in the upper extremities. Despite previously being able to lift over 200 pounds on the bench press, this capability had decreased to 135 pounds over this time. He did not experience any difficulty swallowing, shortness of breath, double vision, or weakness in the lower extremities. Despite adhering to a strict strength training regimen, his symptoms first became noticeable during a fire response, where moderate exertion resulted in significant fatigue, particularly in his lower limbs. Of note, the patient did not recall any episodes indicative of rhabdomyolysis or instances of intermittent or persistent muscle weakness or fatigue during childhood. An initial investigation revealed a slightly elevated CK&#x000a0;level of 297 U/L (normal range: 46-171 U/L), while his complete blood count (CBC) with differential, basic metabolic panel (BMP), thyroid-stimulating hormone (TSH), and liver function tests (LFT) were unremarkable (Table <xref rid="TAB1" ref-type="table">1</xref>).</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>The results of blood testing in the presented case with muscle fatigue and rhabdomyolysis.</title><p><sup>*</sup>Myositis panel include SAE1 (SUMO activating enzyme), NXP2 (Nuclear matrix protein-2), MDA5 (CADM-140), TIF-1 gamma (155 kDa), Mi-2 (nuclear helicase protein), P155/140, PL-12 (alanyl-tRNA synthetase), PL-7 (threonyl-tRNA synthetase), OJ (isoleucyl-tRNA synthetase), EJ (glycyl-tRNA synthetase), SRP (Signal Recognition Particle), Jo-1 (Histidyl-tRNA Synthetase), Ku, Smith/RNP (ENA), PM/Scl 100, SSA-52 (Ro52), SSA-60 (Ro60), Fibrillarin (U3 RNP) antibodies</p><p>BUN: blood urea nitrogen; AST:&#x000a0;aspartate aminotransferase; ALT:&#x000a0;alanine aminotransferase; CK:&#x000a0;creatine kinase; TSH:&#x000a0;thyroid-stimulating hormone; ESR:&#x000a0;erythrocyte sedimentation rate; CRP:&#x000a0;C-reactive protein; GAA:&#x000a0;acid alpha-glucosidase</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Measurements</td><td colspan="4" rowspan="1">Results</td><td rowspan="1" colspan="1">Reference Range</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">June 2023</td><td rowspan="1" colspan="1">August 2023</td><td rowspan="1" colspan="1">February 2024</td><td rowspan="1" colspan="1">March 2024</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">WBC count</td><td rowspan="1" colspan="1">4.97</td><td rowspan="1" colspan="1">4.97</td><td rowspan="1" colspan="1">4.42</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">4.00-10.8 K/uL</td></tr><tr><td rowspan="1" colspan="1">RBC count</td><td rowspan="1" colspan="1">4.82</td><td rowspan="1" colspan="1">4.82</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">4.70-6.10 M/uL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Platelet count</td><td rowspan="1" colspan="1">220</td><td rowspan="1" colspan="1">220</td><td rowspan="1" colspan="1">204</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">150-400 K/uL</td></tr><tr><td rowspan="1" colspan="1">Sodium</td><td rowspan="1" colspan="1">137</td><td rowspan="1" colspan="1">138</td><td rowspan="1" colspan="1">141</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">134-145 mmol/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Potassium</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">4.2</td><td rowspan="1" colspan="1">4.1</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">3.5-5.1 mmol/L</td></tr><tr><td rowspan="1" colspan="1">Chloride</td><td rowspan="1" colspan="1">103</td><td rowspan="1" colspan="1">103</td><td rowspan="1" colspan="1">106</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">98-107 mmol/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">BUN</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">9-23 mg/dL</td></tr><tr><td rowspan="1" colspan="1">Creatinine</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0.6-1.10 mg/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Glucose</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">97</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">74-100 mg/dL</td></tr><tr><td rowspan="1" colspan="1">Calcium</td><td rowspan="1" colspan="1">9.2</td><td rowspan="1" colspan="1">8.9</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">8.3-10.6 mg/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Magnesium</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1.6-2.6 mg/dL</td></tr><tr><td rowspan="1" colspan="1">Phosphate</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">3.1</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">2.3-4.6 mg/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">AST</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">15-34 U/L</td></tr><tr><td rowspan="1" colspan="1">ALT</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">7-40 U/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CK</td><td rowspan="1" colspan="1">297</td><td rowspan="1" colspan="1">297</td><td rowspan="1" colspan="1">4000</td><td rowspan="1" colspan="1">176</td><td rowspan="1" colspan="1">46-194 U/L</td></tr><tr><td rowspan="1" colspan="1">Aldolase</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">4.3</td><td rowspan="1" colspan="1">8.3</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1.2-7.6 U/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">TSH</td><td rowspan="1" colspan="1">1.46</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0.55-4.78 uIU/mL</td></tr><tr><td rowspan="1" colspan="1">ESR</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#x0003c;1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#x0003c;=15 mm/hr</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">&#x0003c;0.05</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#x0003c;1.0 mg/L</td></tr><tr><td rowspan="1" colspan="1">Antinuclear antibody screen</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Acetylcholine receptor-modulating antibody</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0-45%</td></tr><tr><td rowspan="1" colspan="1">Acetylcholine receptor-blocking antibody</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0-26%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Acetylcholine receptor-binding antibody</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0-0.4 nmol/L</td></tr><tr><td rowspan="1" colspan="1">MuSK antibody</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Total lactate dehydrogenase</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">187</td><td rowspan="1" colspan="1">189</td><td rowspan="1" colspan="1">182</td><td rowspan="1" colspan="1">105-230 U/L</td></tr><tr><td rowspan="1" colspan="1">Myositis antibody expanded panel<sup>*</sup>
</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Uric acid</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">3.3-8.0 mg/dL</td></tr><tr><td rowspan="1" colspan="1">HbA1C</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">5.3</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#x0003c;5.6%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Anaplasma (ehrlichiosis) smear</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">Babesia smear</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Pompe GAA activity in leukocytes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">17.6</td><td rowspan="1" colspan="1">5.5-25 nmol/h/mg</td></tr><tr><td rowspan="1" colspan="1">Aerobic forearm test</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Acylcarnitines profile</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Normal</td><td rowspan="1" colspan="1">Normal</td></tr><tr><td rowspan="1" colspan="1">Ammonia</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">7-42 umol/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Beta-hydroxybutyrate</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#x0003c;0.05</td><td rowspan="1" colspan="1">&#x0003c;0.5 mmol/L</td></tr><tr><td rowspan="1" colspan="1">Total carnitine</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">30-70 umol/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Free carnitine</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">23-59 umol/L</td></tr><tr><td rowspan="1" colspan="1">Pyruvate kinase, RBC</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">10.2</td><td rowspan="1" colspan="1">4.6-11.2 U/g Hb</td></tr></tbody></table></table-wrap><p>In August 2023, he was assessed at a local general neurology clinic, where further testing was performed. This included serum antinuclear antibodies (ANA), a myositis expanded antibody panel, lactate dehydrogenase (LDH) isoenzymes, aldolase, acetylcholine receptor antibody panel, anti-MuSK antibody test, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). All these tests returned unremarkable results (Table <xref rid="TAB1" ref-type="table">1</xref>).</p><p>In February 2024, several months after his initial consultation, the patient experienced a significant episode characterized by muscle stiffness, pain, and fatigue, which progressively worsened over several days. He reported severe muscle soreness, subjective weakness, and an inability to lift his 33-pound dog in a pool. Additionally, he observed that his urine had become progressively darker despite maintaining adequate hydration. Upon presenting to the emergency department, his CK&#x000a0;levels were found to be elevated to 4000 U/L, alongside elevated aldolase levels at 8.3 U/L and mildly elevated aspartate aminotransferase (AST) at 59 U/L and alanine aminotransferase (ALT) at 47 U/L. He was treated with intravenous fluids and required a five-day inpatient stay for monitoring, during which his CK levels gradually normalized to 192 U/L. Further diagnostic tests, including&#x000a0;ANA,&#x000a0;CRP, ESR, and testing for anaplasmosis and babesiosis, yielded unremarkable results. The nerve conduction study (Table <xref rid="TAB2" ref-type="table">2</xref>) and electromyography (Table <xref rid="TAB3" ref-type="table">3</xref>) were also unremarkable for any myopathy or large-fiber peripheral neuropathy.</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Nerve conduction studies (NCS) in the presented case with muscle fatigue and rhabdomyolysis.</title><p>AHB: abductor hallucis; EDB: extensor digitorum brevis; NL: normal</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td colspan="1" rowspan="2">Site</td><td colspan="2" rowspan="1">Latency (ms)</td><td colspan="2" rowspan="1">Amplitude&#x000a0;(motor=mV; sensory=&#x000b5;V)</td><td colspan="2" rowspan="1">Conduction velocity (m/s)</td></tr><tr><td rowspan="1" colspan="1">Patient&#x02019;s value</td><td rowspan="1" colspan="1">NL range</td><td rowspan="1" colspan="1">Patient&#x02019;s value</td><td rowspan="1" colspan="1">NL range</td><td rowspan="1" colspan="1">Patient&#x02019;s value</td><td rowspan="1" colspan="1">NL range</td></tr><tr style="background-color:#ccc"><td colspan="7" rowspan="1">Right peroneal (EDB) motor</td></tr><tr><td rowspan="1" colspan="1">Ankle</td><td rowspan="1" colspan="1">3.6</td><td rowspan="1" colspan="1">&#x000a0;&#x0003c;6.5</td><td rowspan="1" colspan="1">5.1</td><td rowspan="1" colspan="1">&#x000a0;&#x0003e;1.10</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Below the fibular head</td><td rowspan="1" colspan="1">9.7</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">5.3</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">&#x0003e;36</td></tr><tr><td rowspan="1" colspan="1">Lateral popliteal fossa</td><td rowspan="1" colspan="1">11.5</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">5.1</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">&#x02265;42</td></tr><tr style="background-color:#ccc"><td colspan="7" rowspan="1">Right tibial (AHB) motor</td></tr><tr><td rowspan="1" colspan="1">Ankle</td><td rowspan="1" colspan="1">6.1</td><td rowspan="1" colspan="1">&#x000a0;&#x0003c;6.1</td><td rowspan="1" colspan="1">16.6</td><td rowspan="1" colspan="1">&#x000a0;&#x0003e;5.3</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Knee</td><td rowspan="1" colspan="1">13.2</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">11.6</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">&#x02265;42</td></tr><tr><td colspan="7" rowspan="1">Right sural sensory</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Calf-lateral malleolus</td><td rowspan="1" colspan="1">3.5</td><td rowspan="1" colspan="1">&#x0003c;4.5</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">&#x0003e;4</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">&#x02265;40</td></tr><tr><td colspan="7" rowspan="1">Right superficial peroneal sensory</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Wrist-digit V</td><td rowspan="1" colspan="1">3.4</td><td rowspan="1" colspan="1">&#x0003c;4.2</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">&#x0003e;5</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">&#x02265;40</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Electromyography (EMG) in the presented case with muscle fatigue and rhabdomyolysis.</title><p>Fasc: fasciculation potentials; FDI: first dorsal interosseous; Fibs: fibrillation potentials; FCR:&#x000a0;flexor carpi radialis;&#x000a0;NL: normal; Poly: polyphasic; PSW: positive sharp waves; Recrt: recruitment; Spon Disc: spontaneous discharges</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Muscle (all right side)</td><td rowspan="1" colspan="1">Ins Act</td><td rowspan="1" colspan="1">Fibs/ PSW</td><td rowspan="1" colspan="1">Fasc</td><td rowspan="1" colspan="1">Spon Disc</td><td rowspan="1" colspan="1">Amplitude</td><td rowspan="1" colspan="1">Duration</td><td rowspan="1" colspan="1">Poly</td><td rowspan="1" colspan="1">Recrt</td><td rowspan="1" colspan="1">Activation</td></tr><tr><td rowspan="1" colspan="1">Medial gastrocnemius</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Lateral gastrocnemius</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr><td rowspan="1" colspan="1">Tibialis anterior</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Vastus lateralis</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr><td rowspan="1" colspan="1">Vastus medialis</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">FDI</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr><td rowspan="1" colspan="1">FCR</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Triceps</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr><td rowspan="1" colspan="1">Biceps</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Deltoid</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td></tr><tr><td rowspan="1" colspan="1">Mid lumbar paraspinal</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Mid thoracic Paraspinal</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">NL</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><p>The patient was evaluated in our neuromuscular clinic in March 2024 for further assessment of his hyperCKemia and subjective muscle weakness, stiffness, and myalgias. He reported no relevant medical history, medication use, or family history of neuromuscular conditions, and he denied smoking or drug use. The patient did not also recall any specific triggers for his symptoms, including particular foods or infections (e.g., COVID-19), prior to the onset of his symptoms or before he was later hospitalized. A neurological examination revealed slight asymmetry in scapular muscle bulk but was otherwise unremarkable. Further investigations included tests for Pompe disease (acid alpha-glucosidase, or GAA) enzyme activity, a quantitative acylcarnitine profile, free and total carnitine levels, urine acetone, beta-hydroxybutyrate, and ammonia levels, as well as an aerobic forearm test. All these tests returned unremarkable findings (Table <xref rid="TAB1" ref-type="table">1</xref>).</p><p>Following an inconclusive autoimmune and metabolic workup, genetic testing via the Invitae comprehensive neuromuscular disorder panel identified a heterozygous <italic>LPIN1 </italic>exon 18 deletion. There were no other detected mutations in the <italic>LPIN1 </italic>gene, potentially ruling out the possibility of compound heterozygous mutations in this case. The sole variant detected was a gross deletion of the genomic region encompassing exon 18. This out-of-frame deletion is expected to create a premature termination codon, leading to an absent or disrupted protein product. Loss-of-function variants in <italic>LPIN1</italic> are known to be pathogenic [<xref rid="REF3" ref-type="bibr">3</xref>-<xref rid="REF6" ref-type="bibr">6</xref>]. As a result, the patient was advised to maintain good fluid intake and to avoid potential triggers such as strenuous exercise, fasting, and febrile illnesses to help prevent episodes of rhabdomyolysis.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>This case involves an adult man experiencing recurrent, moderate rhabdomyolysis due to a heterozygous <italic>LPIN1 </italic>exon deletion, with an otherwise unremarkable workup. To our knowledge, this is the first reported case of recurrent rhabdomyolysis in a heterozygous <italic>LPIN1 </italic>adult patient without prior exposure to statins.</p><p>The significance of <italic>LPIN1</italic> mutations in severe, recurrent rhabdomyolysis was first identified by Zeharia et al. in 2008 [<xref rid="REF5" ref-type="bibr">5</xref>]. They reported three pediatric patients, all under the age of six, who experienced episodes of severe rhabdomyolysis despite an otherwise normal workup. Further research by Michot et al. in 2010 highlighted that homozygous or compound heterozygous <italic>LPIN1</italic> mutations were present in 56% of 29 patients under the age of five, with CK levels exceeding 10,000 U/L during rhabdomyolysis episodes [<xref rid="REF3" ref-type="bibr">3</xref>]. These findings positioned <italic>LPIN1</italic> mutations as the second most common cause of recurrent rhabdomyolysis, following fatty acid oxidation disorders. In a subsequent study conducted in 2012, Michot et al. [<xref rid="REF4" ref-type="bibr">4</xref>] expanded their cohort to include older patients and those with milder forms of rhabdomyolysis (CK &#x0003c;10,000 U/L). Among the 35 patients studied, 33 were under the age of six at symptom onset, with one eight-year-old and one 42-year-old patient. All patients experienced severe rhabdomyolysis, and 11 out of the 35 patients died during an episode [<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>The most common pathogenic mutation in <italic>LPIN1</italic> is the exon 18 deletion, which accounts for 86% of mutations in Caucasian patients [<xref rid="REF4" ref-type="bibr">4</xref>]. This deletion impacts amino acids E766-S838 in the C-terminus of the <italic>LPIN1</italic> protein, leading to a complete loss of function [<xref rid="REF7" ref-type="bibr">7</xref>]. While<italic> LPIN1 </italic>mutations predominantly affect pediatric populations, there have been isolated cases of adult-onset symptoms. These include a 42-year-old patient in the Michot et al. study in 2012 [<xref rid="REF4" ref-type="bibr">4</xref>] and a 46-year-old patient reported by Minton et al. in 2020 [<xref rid="REF8" ref-type="bibr">8</xref>], both of whom had homozygous or compound heterozygous mutations. Zeharia et al. [<xref rid="REF5" ref-type="bibr">5</xref>] also described a heterozygous adult relative with statin-associated myopathy. However, prior to this case, there have been no reported instances of adult-onset recurrent hyperCKemia in heterozygous patients without statin use.</p><p>The molecular mechanisms leading to muscle injury in <italic>LPIN1</italic> deficiency are not fully understood. <italic>LPIN1</italic> is a crucial enzyme involved in lipid metabolism and energy homeostasis. To understand how the loss of <italic>LPIN1</italic> activity leads to myocyte injury, investigators have used various mouse and cell culture models [<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF9" ref-type="bibr">9</xref>,<xref rid="REF10" ref-type="bibr">10</xref>]. Notably, fatty liver dystrophy (fld) mice or those with muscle-specific <italic>LPIN1</italic> deletion show a chronic, progressive myopathic phenotype, distinct from the acute or recurrent/episodic syndrome seen in humans [<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF9" ref-type="bibr">9</xref>,<xref rid="REF10" ref-type="bibr">10</xref>]. This myopathy is characterized by myocyte necrosis, regenerative myofibrils, and fibrotic lesions [<xref rid="REF11" ref-type="bibr">11</xref>]. In <italic>LPIN1</italic>-deficient mice, damaged mitochondria with reduced oxidative capacity accumulate due to impaired mitophagy [<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF9" ref-type="bibr">9</xref>]. Interestingly, transgenic muscle-specific overexpression of <italic>LPIN1</italic> can rescue the phenotype of fld mice, indicating a myocyte intrinsic effect [<xref rid="REF9" ref-type="bibr">9</xref>]. Loss of <italic>LPIN1</italic> in skeletal muscle leads to very low phosphatidate phosphatase (PAP) enzyme activity and accumulation of phosphatidic acid, which impairs autophagy [<xref rid="REF11" ref-type="bibr">11</xref>]. The mechanistic explanations for impaired autophagy vary by model. For instance, muscle-specific <italic>LPIN1</italic> knockouts exhibit increased muscle diacylglycerol (DAG) content, while fld mice display DAG depletion, affecting muscle lipid content and protein kinase D (PKD) activation [<xref rid="REF9" ref-type="bibr">9</xref>]. This leads to defective autophagy and may influence myocyte differentiation. In muscle-specific <italic>LPIN1</italic> knockout mice, the PKD mechanism does not apply due to DAG accumulation. However, these mice exhibit signs of lipotoxic and sarcoplasmic reticular stress [<xref rid="REF10" ref-type="bibr">10</xref>]. Treatment with agents that enhance fat oxidation or chemical chaperones to alleviate stress can mitigate myopathy in these mice [<xref rid="REF10" ref-type="bibr">10</xref>]. This demonstrates the complex interplay of lipid metabolism in muscle health and disease.</p><p>In conclusion, while adult-onset rhabdomyolysis associated with <italic>LPIN1</italic> deficiency is rare, this case underscores the importance of considering it as a differential diagnosis in patients with recurrent rhabdomyolysis, especially when CK levels normalize between episodes and the workup is otherwise unremarkable. With the increasing use of genomic testing, we anticipate that more cases will be identified in the future.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We reported a rare instance of episodic rhabdomyolysis in an adult patient carrying a heterozygous <italic>LPIN1</italic> gene mutation. This case underscores the necessity of considering <italic>LPIN1 </italic>mutations in the differential diagnosis for adult patients without prior statin therapy or a family history of neuromuscular disorders, who present with such symptoms. Genetic testing is pivotal in confirming the diagnosis when clinical suspicion arises.</p><p>Currently, there is no definitive cure for episodic rhabdomyolysis linked to <italic>LPIN1</italic> mutations, characterized by subjective fatigue, muscle weakness, and stiffness. Treatment remains primarily supportive, focusing on adequate hydration and avoiding known triggering factors.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Mehdi Ghasemi, Naman Bareja, Rafail A. Chionatos, Camelia Valhuerdi Porto, Nikita Srinivasan</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Mehdi Ghasemi, Naman Bareja, Rafail A. Chionatos, Camelia Valhuerdi Porto, Nikita Srinivasan</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Mehdi Ghasemi, Naman Bareja, Rafail A. Chionatos, Camelia Valhuerdi Porto, Nikita Srinivasan</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Mehdi Ghasemi, Naman Bareja, Rafail A. Chionatos, Camelia Valhuerdi Porto, Nikita Srinivasan</p><p><bold>Supervision:</bold>&#x000a0; Mehdi Ghasemi</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>The lipin family: mutations and metabolism</article-title><source>Curr Opin Lipidol</source><person-group>
<name><surname>Reue</surname><given-names>K</given-names></name>
</person-group><fpage>165</fpage><lpage>170</lpage><volume>20</volume><year>2009</year><pub-id pub-id-type="pmid">19369868</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns</article-title><source>J Biol Chem</source><person-group>
<name><surname>Donkor</surname><given-names>J</given-names></name>
<name><surname>Sariahmetoglu</surname><given-names>M</given-names></name>
<name><surname>Dewald</surname><given-names>J</given-names></name>
<name><surname>Brindley</surname><given-names>DN</given-names></name>
<name><surname>Reue</surname><given-names>K</given-names></name>
</person-group><fpage>3450</fpage><lpage>3457</lpage><volume>282</volume><year>2007</year><pub-id pub-id-type="pmid">17158099</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood</article-title><source>Hum Mutat</source><person-group>
<name><surname>Michot</surname><given-names>C</given-names></name>
<name><surname>Hubert</surname><given-names>L</given-names></name>
<name><surname>Brivet</surname><given-names>M</given-names></name>
<etal/>
</person-group><fpage>0</fpage><lpage>73</lpage><volume>31</volume><year>2010</year></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia</article-title><source>J Inherit Metab Dis</source><person-group>
<name><surname>Michot</surname><given-names>C</given-names></name>
<name><surname>Hubert</surname><given-names>L</given-names></name>
<name><surname>Romero</surname><given-names>NB</given-names></name>
<etal/>
</person-group><fpage>1119</fpage><lpage>1128</lpage><volume>35</volume><year>2012</year><pub-id pub-id-type="pmid">22481384</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood</article-title><source>Am J Hum Genet</source><person-group>
<name><surname>Zeharia</surname><given-names>A</given-names></name>
<name><surname>Shaag</surname><given-names>A</given-names></name>
<name><surname>Houtkooper</surname><given-names>RH</given-names></name>
<etal/>
</person-group><fpage>489</fpage><lpage>494</lpage><volume>83</volume><year>2008</year><pub-id pub-id-type="pmid">18817903</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>A novel therapeutic approach for LPIN1 mutation-associated rhabdomyolysis--the Austrian experience</article-title><source>Muscle Nerve</source><person-group>
<name><surname>Pichler</surname><given-names>K</given-names></name>
<name><surname>Scholl-Buergi</surname><given-names>S</given-names></name>
<name><surname>Birnbacher</surname><given-names>R</given-names></name>
<etal/>
</person-group><fpage>437</fpage><lpage>439</lpage><volume>52</volume><year>2015</year><pub-id pub-id-type="pmid">26111941</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Rhabdomyolysis-associated mutations in human LPIN1 lead to loss of phosphatidic acid phosphohydrolase activity</article-title><source>JIMD Rep</source><person-group>
<name><surname>Schweitzer</surname><given-names>GG</given-names></name>
<name><surname>Collier</surname><given-names>SL</given-names></name>
<name><surname>Chen</surname><given-names>Z</given-names></name>
<etal/>
</person-group><fpage>113</fpage><lpage>122</lpage><volume>23</volume><year>2015</year><pub-id pub-id-type="pmid">25967228</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>A rare case of adult onset LPIN1 associated rhabdomyolysis</article-title><source>Neuromuscul Disord</source><person-group>
<name><surname>Minton</surname><given-names>T</given-names></name>
<name><surname>Forrester</surname><given-names>N</given-names></name>
<name><surname>Baba</surname><given-names>SA</given-names></name>
<name><surname>Urankar</surname><given-names>K</given-names></name>
<name><surname>Brady</surname><given-names>S</given-names></name>
</person-group><fpage>241</fpage><lpage>245</lpage><volume>30</volume><year>2020</year><pub-id pub-id-type="pmid">32115342</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle</article-title><source>Cell Metab</source><person-group>
<name><surname>Zhang</surname><given-names>P</given-names></name>
<name><surname>Verity</surname><given-names>MA</given-names></name>
<name><surname>Reue</surname><given-names>K</given-names></name>
</person-group><fpage>267</fpage><lpage>279</lpage><volume>20</volume><year>2014</year><pub-id pub-id-type="pmid">24930972</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Lipin1 deficiency causes sarcoplasmic reticulum stress and chaperone-responsive myopathy</article-title><source>EMBO J</source><person-group>
<name><surname>Rashid</surname><given-names>T</given-names></name>
<name><surname>Nemazanyy</surname><given-names>I</given-names></name>
<name><surname>Paolini</surname><given-names>C</given-names></name>
<etal/>
</person-group><volume>38</volume><year>2019</year></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Regulation of signaling and metabolism by Lipin-mediated phosphatidic acid phosphohydrolase activity</article-title><source>Biomolecules</source><person-group>
<name><surname>Lutkewitte</surname><given-names>AJ</given-names></name>
<name><surname>Finck</surname><given-names>BN</given-names></name>
</person-group><volume>10</volume><year>2020</year></element-citation></ref></ref-list></back></article>